マウス実験結核症におけるリファンピシンとイソニアジッドの治療効果の比較

概要

論文の詳細を見る
There is an increasing amount of information to consider that rifampicin is one of the most powerful chemotherapeutics against tuberculosis. An experiment was then carried out to compare the therapeutic effect of rifampicin with that of isoniazid on experimental mouse tuberculosis. Evaluation of the effect was made by following the fate of infecting tubercle bacilli in the treated mice as revealed by enumeration of spleen and lung viable units with one or two week intervals. Particular concern was placed on the effect of rifampicin on the bacilli which were introduced as an inoculum for the secondary infection as shown in Fig. 1.<BR>The results are demonstrated in Figs. 2 and 3. The oral administration of rifampicin in the daily dose of 0.75mg was proved to be more effective than the intraperitoneal injection with 0.5mg isoniazid 6 times per week. This superior effect of rifampicin to isoniazid was expressed most evidently on the bacilli of the secondary inoculum whose multiplication was inhibited in the spleen.
日本結核病学会の論文